Biogen to acquire novel clinical-stage asset from Pfizer14 Jan 2020
PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.
Biogen has agreed to acquire from Pfizer PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases.
In particular, Biogen plans to develop the Phase I asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). The purchase will include an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.
“This asset is highly complementary to our existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases,” said Alfred Sandrock Jr., Executive Vice President, Research and Development and Chief Medical Officer at Biogen. “Many patients with Alzheimer’s and Parkinson’s suffer from debilitating sleep disorders and agitation, and we believe that the regulation of the circadian rhythm may hold promise in addressing these challenging behavioral and neurological symptoms.”
CK1 is a key regulator of the ‘central clock,’ the suprachiasmatic nucleus of the hypothalamus, that controls circadian rhythm and impacts nearly all vital physiology and metabolism. The disruption of circadian rhythm is associated with various psychiatric and neurological diseases, including certain important symptoms of AD and PD.
Sundowning is a symptom that impacts 20% or more of AD patients who become confused, anxious, aggressive, agitated or restless later in the day. ISWRD is a circadian rhythm disorder where patients experience fragmented nighttime sleep leading to daytime sleepiness, severe fatigue and difficulty with activities of daily living.
It is one of the non-motor symptoms of PD, and usually increases in frequency over the course of the disease and disability progression. Biogen will explore the potential of PF-05251749 to improve behavioral disturbances of Sundowning in AD by correcting circadian rhythm, as well as its potential to treat symptoms of ISWRD to improve daytime wakefulness, sleep quality, behavior and daily function.
PF-05251749 has previously demonstrated an acceptable safety profile and proof of mechanism in a Phase Ia clinical study. Biogen aims to initiate a Phase Ib study in Q4 2020.
New blood test able to detect 50 cancer types
31 Mar 2020
Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.Read more
European patent granted for amatoxin conjugates for tumor therapy
31 Mar 2020
The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.Read more
ProBioGen selected for development and large-scale manufacturing services
24 Mar 2020
The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.Read more
Positive update on the development of new XF‐platform drug formulations
24 Mar 2020
Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.Read more
Alvotech and DKSH partner to bring key biosimilar to Asia
24 Mar 2020
Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.Read more
Codexis and Takeda collaborate to advance novel gene therapies
23 Mar 2020
Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.Read more
Vaxxas HD-MAP to deliver vaccines directly to the skin
17 Mar 2020
Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.Read more
Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19
16 Mar 2020
The trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients.Read more
Technique improves drug delivery system characterization
16 Mar 2020
Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.Read more
Nanoform and Orion collaborate on 'nanoformed' APIs
9 Mar 2020
Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation